Version 2.1.1.0

Abstract

Grant Number:	1R43GM068173-01
PI Name:	BRIAN, PAUL
PI Email:	paul.brian@cubist.com
PI Title:
Project Title:	Modification of daptomycin by combinatorial biosynthesis

Abstract: DESCRIPTION (provided by applicant): The antibiotic daptomycin is produced by the Gram-positive bacterium Streptomyces roseosporus and is the first in a new class of investigational drugs called lipopeptides that is being developed by Cubist for the treatment of serious and life-threatening infections caused by Gram-positive pathogens. The goal of this phase I application is to develop a system that will allow the rapid manipulation of the daptomycin biosynthetic gene cluster. These tools would then be used in phase II of the application to elucidate the structure-activity realtionships (SAR) of daptomycin and use this information to create derivatives of daptomycin with increased potency against vancomycin resistant pathogens.

Thesaurus Terms:
Streptomyces, antibiotic, chemical structure function, combinatorial chemistry, cyclic peptide, drug design /synthesis /production, molecular cloning
biotherapeutic agent, stereochemistry
biotechnology, plasmid

Institution:	CUBIST PHARMACEUTICALS, INC.
	65 HAYDEN AVE
	LEXINGTON, MA 02421
Fiscal Year:	2003
Department:
Project Start:	01-JUL-2003
Project End:	31-DEC-2003
ICD:	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
IRG:	ZRG1

---